# Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers

> **NCT01406925** · PHASE1 · COMPLETED · sponsor: **Norgine** · enrollment: 12 (actual)

## Conditions studied

- Fecal Incontinence

## Interventions

- **DRUG:** Placebo control
- **DRUG:** NRL001 cream

## Key facts

- **NCT ID:** NCT01406925
- **Lead sponsor:** Norgine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2007-05
- **Final completion:** 2007-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2011-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01406925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01406925, "Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01406925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*